BioSpace News Archive

3DBio Therapeutics, an emerging leader in the field of 3D-bioprinting for human therapeutic use, today announced Scott Dylla, Ph.D has joined its Board of Directors.

Icosavax, Inc. today announced the launch of the company’s COVID-19 vaccine program with preclinical data on the company’s VLP vaccine candidate, IVX-411, which comprises a virus-like particle (VLP) displaying the SARS-CoV-2 receptor-binding domain (RBD) in a highly immunogenic array.

Muse® by Interaxon Inc., a leading consumer neurotechnology and meditation company, appoints neuroscientist and digital medicine expert Walter Greenleaf as Chief Science Officer.

Protagonist Therapeutics, Inc. reported that on October 31, 2020, it issued an inducement award to Nora Boyer, the Company’s recently hired Vice President, Medical Affairs, in accordance with the terms of Ms. Boyer’s employment offer letter.

This week, leadership from the U.S. Food and Drug Administration, the U.S. Customs and Border Protection (CBP), and the U.S. Immigration and Customs Enforcement, Homeland Security Investigations (ICE-HSI) signed a Memorandum of Understanding (MOU) to stop harmful products that pose a threat to public health and attempt to enter the U.S. through International Mail Facilities (IMFs).

Core One Labs Inc. (CSE:COOL)(OTC PINK:CLABF), (Frankfurt:LD62) (WKN: A2P8K3) (the “Company”) is pleased to announce it has entered into a Letter of Intent (the “LOI”) with High Tower Capital Inc. (“High Tower”) dated effective October 15, 2020 to sell certain assets and subsidiaries to High Tower for CAD$3,000,000 and the assumption of USD$4,015,885 in related liabilities

Avantor, Inc. announced the pricing of the previously announced private offering by its wholly-owned subsidiary, Avantor Funding, Inc., of €650.0 million aggregate principal amount of 2.625% Senior First Lien Notes due 2025.

Xeris Pharmaceuticals, Inc. announced that on October 28, 2020, the Compensation Committee of Xeris’ Board of Directors granted non-qualified stock options for an aggregate of 36,250 share of its common stock to 15 new employee under Xeris’ Inducement Equity Plan.

Tandem Diabetes Care, Inc., a leading insulin delivery and diabetes technology company, announced that management will present a company update at the following virtual investor conferences:

CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live audio webcast on Thursday, November 5, 2020 at 4:30 p.m. Eastern Time to discuss financial results for the third quarter and nine months ended September 30, 2020 and to provide a business update.